The 36-month beta value for PRME is also noteworthy at 2.19. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for PRME is 50.58M, and at present, short sellers hold a 32.77% of that float. The average trading volume of PRME on September 30, 2024 was 698.39K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PRME) stock’s latest price update
The stock price of Prime Medicine Inc (NASDAQ: PRME) has jumped by 25.21 compared to previous close of 3.46. Despite this, the company has seen a gain of 20.34% in its stock price over the last five trading days. benzinga.com reported 2024-09-30 that On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.
PRME’s Market Performance
PRME’s stock has risen by 20.34% in the past week, with a monthly rise of 0.52% and a quarterly drop of -20.94%. The volatility ratio for the week is 6.03% while the volatility levels for the last 30 days are 7.62% for Prime Medicine Inc The simple moving average for the last 20 days is 13.72% for PRME’s stock, with a simple moving average of -30.89% for the last 200 days.
Analysts’ Opinion of PRME
Many brokerage firms have already submitted their reports for PRME stocks, with H.C. Wainwright repeating the rating for PRME by listing it as a “Buy.” The predicted price for PRME in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on May 20, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see PRME reach a price target of $10. The rating they have provided for PRME stocks is “Buy” according to the report published on May 16th, 2024.
Chardan Capital Markets gave a rating of “Buy” to PRME, setting the target price at $17 in the report published on April 22nd of the current year.
PRME Trading at -0.88% from the 50-Day Moving Average
After a stumble in the market that brought PRME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.06% of loss for the given period.
Volatility was left at 7.62%, however, over the last 30 days, the volatility rate increased by 6.03%, as shares surge +6.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.83% lower at present.
During the last 5 trading sessions, PRME rose by +26.97%, which changed the moving average for the period of 200-days by -39.62% in comparison to the 20-day moving average, which settled at $3.82. In addition, Prime Medicine Inc saw -51.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRME starting from NELSEN ROBERT, who purchase 3,200,000 shares at the price of $6.25 back on Feb 15 ’24. After this action, NELSEN ROBERT now owns 3,200,000 shares of Prime Medicine Inc, valued at $20,000,000 using the latest closing price.
ARCH Venture Partners XII, LLC, the 10% Owner of Prime Medicine Inc, purchase 3,200,000 shares at $6.25 during a trade that took place back on Feb 15 ’24, which means that ARCH Venture Partners XII, LLC is holding 3,200,000 shares at $20,000,000 based on the most recent closing price.
Stock Fundamentals for PRME
Current profitability levels for the company are sitting at:
- -378.2 for the present operating margin
The net margin for Prime Medicine Inc stands at -367.92. The total capital return value is set at -0.94. Equity return is now at value -99.58, with -80.45 for asset returns.
Based on Prime Medicine Inc (PRME), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -4.72.
Currently, EBITDA for the company is -186.64 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 808.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.23.
Conclusion
In summary, Prime Medicine Inc (PRME) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
